Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for oncology and autoimmune and inflammatory diseases. News commonly centers on bexobrutideg (NX-5948), a Bruton’s tyrosine kinase degrader, including clinical data in chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, as well as updates tied to the DAYBreak development program.
Company updates also cover Nurix’s DEL-AI discovery platform, preclinical degrader programs against targets such as pan-mutant BRAF, CBL-B and Aurora kinase A, and partnered inflammation and immunology programs involving IRAK4 and STAT6 degraders. Recurring announcements include financial results, corporate presentations, scientific meeting data, pipeline progress, capital actions and board or governance changes.
Nurix Therapeutics (NRIX) has granted inducement awards to 16 new employees on April 8, 2025, as part of their 2024 Equity Inducement Plan. The awards include:
- Stock options to purchase 79,950 shares with a 10-year term at $9.26 per share exercise price
- Restricted stock units (RSUs) representing 54,750 shares
The stock options vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. RSUs also vest over 4 years, with 25% vesting on April 30, 2026, and the remainder vesting quarterly. Both awards require continued employment with Nurix for vesting.
Nurix Therapeutics (NRIX) reported Q1 2025 financial results and corporate updates. The company's lead BTK degrader NX-5948 received the nonproprietary name 'bexobrutideg' and FDA Orphan Drug Designation for Waldenström macroglobulinemia. Revenue increased to $18.5M from $16.6M year-over-year, including $7M in Sanofi collaboration milestones.
The company achieved significant milestones, including a $15M license extension fee from Sanofi and strengthened its leadership with Roy D. Baynes joining the board and John Northcott as chief commercial officer. R&D expenses rose to $69.7M from $50.0M, while G&A expenses slightly decreased to $11.7M.
The company reported a net loss of $56.4M ($0.67 per share) compared to $41.5M ($0.76 per share) in the previous year. Nurix maintains a strong financial position with $549.7M in cash and marketable securities, excluding recent milestone payments.
Nurix Therapeutics (NRIX) has licensed an undisclosed drug discovery program to Sanofi targeting a novel transcription factor for autoimmune diseases. The target, distinct from their STAT6 program, is a central regulator of inflammation identified using Nurix's DEL-AI platform.
The deal brings $15 million in license extension fees to Nurix, totaling $105 million received from Sanofi to date under their 2019 collaboration agreement. Nurix remains eligible for up to $465 million in additional milestone payments plus potential royalties. The company retains an option to co-develop and co-promote in the United States, with both parties splitting U.S. profits and losses.
This partnership expansion demonstrates the success of Nurix's DEL-AI discovery platform in developing innovative drugs for previously undruggable targets, while providing non-dilutive capital and pipeline expansion opportunities.
Nurix Therapeutics (NRIX) announced its upcoming participation at the AACR 2025 Annual Meeting in Chicago, presenting research through two oral and two poster presentations. The company will showcase preclinical data from its DEL-AI platform and several degrader programs.
The oral presentations will focus on: 1) DEL-AI's proteome-wide in silico screening using machine learning foundation models, and 2) selective, orally bioavailable Aurora A degraders for cancer treatment. The poster presentations will highlight: 1) NRX-0305, a pan-mutant BRAF degrader showing broad preclinical efficacy and brain penetrance, and 2) NX-5948, a CNS-penetrant catalytic BTK degrader that challenges conventional CNS drug design principles.
Nurix Therapeutics (NRIX) announced that its drug bexobrutideg (NX-5948) has received Orphan Drug Designation (ODD) from the FDA for treating Waldenström macroglobulinemia (WM). Bexobrutideg is an oral, brain-penetrant BTK degrader currently in Phase 1a/b clinical trials for relapsed/refractory B-cell malignancies.
The ODD grants several benefits including tax credits for clinical testing, FDA fee waivers, and seven years of market exclusivity upon approval. The drug represents a new class of targeted protein degraders, marked by the novel 'deg' suffix, distinguishing it from traditional inhibitors that use the 'ib' suffix.
The designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström Macroglobulinemia. The drug's mechanism involves catalytic degradation of target proteins through the proteasome, potentially eliminating mutant oncoproteins resistant to inhibitor therapy.
Nurix Therapeutics (NRIX) has granted inducement awards to 13 new employees on March 11, 2025, as approved by the company's Compensation Committee under Nasdaq Listing Rule 5635(c)(4). The awards include:
- Stock options to purchase 157,150 shares with a 10-year term and $13.90 exercise price
- Restricted stock unit awards (RSUs) representing 107,500 shares
The stock options vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. RSUs also vest over 4 years, with 25% vesting on April 30, 2026, and the remainder vesting quarterly. Both awards require continued employment with Nurix for vesting.
Nurix Therapeutics (Nasdaq: NRIX) has appointed Roy D. Baynes, MB.Bch., M.Med., Ph.D. to its board of directors. Dr. Baynes, currently executive vice president and chief medical officer of Eikon Therapeutics, brings over 22 years of clinical leadership experience in pharmaceutical and biotech companies.
Previously serving as chief medical officer at Merck, Dr. Baynes supervised the clinical portfolio and developed strategies for numerous medicines, including pembrolizumab (Keytruda). He has been a member of Nurix's Medical Advisory Board since 2023 and has expressed particular interest in the company's protein degradation science and clinical trials of NX-5948 in patients with CLL and Waldenström macroglobulinemia.
Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines for cancer and inflammatory diseases, has announced its participation in two major investor conferences in March 2025.
The company's leadership, including President and CEO Arthur T. Sands, M.D., Ph.D., and CFO Hans van Houte, will attend the Jefferies Biotech on the Beach Summit in Miami Beach for one-on-one meetings on March 11, 2025. They will also participate in the Barclays 27th Annual Global Healthcare Conference in Miami Beach, featuring a fireside chat on March 12, 2025, from 10:00-10:25 a.m. ET.
The fireside chat will be accessible through a live webcast on the Investors section of Nurix's website, with the recording available for 30 days following the event.
Nurix Therapeutics (NRIX) has granted inducement awards to nine new employees as of February 11, 2025. The awards, approved under Nasdaq Listing Rule 5635(c)(4), include stock options to purchase 208,350 shares and restricted stock unit awards (RSUs) for 272,850 shares of common stock.
The stock options, priced at $17.12 per share, will vest over four years with 25% vesting after one year and the remainder vesting monthly. They have a ten-year term. The RSUs will also vest over four years, with 25% vesting after one year and the remainder vesting quarterly. Vesting start dates are January 30, 2025, for employees hired before January 31, 2025, and April 30, 2025, for those hired after.
Nurix Therapeutics (NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's president and CEO, Arthur T. Sands, M.D., Ph.D., will engage in a fireside chat on Tuesday, February 11, 2025, at 12:40 p.m. ET.
The company, which focuses on developing innovative treatments for cancer and inflammatory diseases, will make the event available through a live webcast. Interested parties can access the webcast through the Investors section of Nurix's website, and the recording will remain accessible for 30 days following the event.